论文部分内容阅读
[目的]探讨康复新液联合三联疗法用于初治失败的幽门螺杆菌(Hp)感染的疗效。[方法]将209例初治失败的Hp感染患者随机分为治疗组和对照组。在雷贝拉唑+左氧氟沙星+克拉霉素标准三联疗法基础上,治疗组加用康复新液,对照组加用依卡贝特纳。2组疗程均为10d,治疗结束4周后复查13/14 C-UBT,观察并比较2组Hp根除率及药物不良反应。[结果]治疗组和对照组Hp根除率分别为93.52%和75.25%,差异有统计学意义(P<0.05)。治疗组物不良反应发生率为5.6%,低于对照组的9.9%,差异有统计学意义(P<0.05)。[结论]康复新液联合标准三联疗法能有效根除Hp感染,并且不良反应小,可用于初治失败的幽门螺杆菌感染。
[Objective] To investigate the curative effect of Kangfuxin Solution combined with triple therapy on initial failure of Helicobacter pylori (Hp) infection. [Methods] 209 patients with untreated Hp infection were randomly divided into treatment group and control group. In the rabeprazole + levofloxacin + clarithromycin standard triple therapy, the treatment group plus rehabilitation of new liquid, the control group plus ecabatine. The two courses of treatment were 10d, 4 weeks after the end of treatment review 13/14 C-UBT, observed and compared two groups of Hp eradication rate and adverse drug reactions. [Results] The eradication rates of Hp in the treatment group and the control group were 93.52% and 75.25%, respectively, with statistical significance (P <0.05). The incidence of adverse reactions in the treatment group was 5.6%, which was lower than that in the control group (9.9%), the difference was statistically significant (P <0.05). [Conclusion] Kangfuxin solution combined with standard triple therapy can eradicate Hp infection effectively and has small adverse reactions. It can be used in the initial treatment of failed Helicobacter pylori infection.